Bone Mineral Density in Children and Adolescents with Congenital Adrenal Hyperplasia

Table 2

Patient characteristics according to gender, congenital adrenal hyperplasia form, Tanner stage, type of corticosteroid treatment, hydrocortisone dose equivalent, and use of fludrocortisone.

Patient	Gender	CAH form	Tanner stage	Corticosteroid treatment	Hydrocortisone dose (mg/m^2/day)	Fludrocortisone dose (mg/day)
1	F	S.W.	M1P1	Prednisolone	4	Y (0.1)
2	F	S.W.	M1P1	Hydrocortisone	18	Y (0.1)
3	F	S.W.	M4P4	Prednisone	6	Y (0.1)
4	F	S.W.	M1P1	Hydrocortisone	15	Y (0.1)
5	F	S.W.	G4P4	Prednisolone	24	Y (0.1)
6	M	S.W.	M5P5	Dexamethasone	3.5	Y (0.1)
7	F	S.V.	M1P1	Prednisolone	14.8	N
8	F	S.V.	M2P2	Prednisolone	11.2	N
9	F	S.V.	M4P5	Prednisolone	18.8	N
10	F	S.W.	M2P4	Prednisolone	8	Y (0.1)
11	F	S.V.	M2P4	Prednisone	18	N
12	F	S.V.	M1P5	Prednisone	14.9	N
13	F	S.V.	M2P1	Prednisolone	3.6	N
14	F	S.W.	M5P5	Prednisolone	11.6	Y (0.1)

CAH: congenital adrenal hyperplasia, F: female, M: male, S.V.: simple-virilising, S.W.: salt-wasting, Y: yes, and N: no.